Literature DB >> 24141559

CDCA7L promotes hepatocellular carcinoma progression by regulating the cell cycle.

Yuan Tian1, Changjun Huang, Hai Zhang, Qingfeng Ni, Sheng Han, Dong Wang, Zeguang Han, Xiangcheng Li.   

Abstract

The cell division cycle-associated 7-like protein (CDCA7L) is a recently-identified target gene of c-Myc which can also interact with c-Myc. It is known to be upregulated in many tumors, however, its role in tumor progression remains unclear. We investigated the role of CDCA7L expression in hepatocellular carcinoma (HCC). We confirmed that CDCA7L is strongly upregulated in human HCC, and demonstrated that ectopic overexpression of CDCA7L promotes HCC cell proliferation and colony formation. Conversely, knockdown of CDCA7L inhibits these malignant phenotypes. In an in vivo model, subcutaneous transplantation of the tumor in nude mice showed that overexpression of CDCA7L can accelerate the tumor growth rate. Mechanistic analyses indicated that CDCA7L was able to activate the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway and regulate the cell cycle, thus promoting HCC progression. Collectively, these findings show that CDCA7L plays a role in promoting the development of HCC and may constitute a potential therapeutic target in HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24141559     DOI: 10.3892/ijo.2013.2142

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  CDCA7L promotes glioma proliferation by targeting CCND1 and predicts an unfavorable prognosis.

Authors:  Qian-Kun Ji; Ji-Wei Ma; Rui-Hua Liu; Xiang-Sheng Li; Fa-Zheng Shen; Li-Yong Huang; Lei Hui; Yan-Juan Ma; Bao-Zhe Jin
Journal:  Mol Med Rep       Date:  2019-06-05       Impact factor: 2.952

2.  Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis.

Authors:  Min Ma; Soumitra Ghosh; Daniele Tavernari; Atul Katarkar; Andrea Clocchiatti; Luigi Mazzeo; Anastasia Samarkina; Justine Epiney; Yi-Ru Yu; Ping-Chih Ho; Mitchell P Levesque; Berna C Özdemir; Giovanni Ciriello; Reinhard Dummer; G Paolo Dotto
Journal:  J Exp Med       Date:  2021-02-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.